GlaxoSmithKline has expanded its alliance with Adaptimmune Therapeutics to accelerate its lead clinical cancer programme toward pivotal trials in synovial sarcoma. The companies signed a strategic collaboration and licensing agreement in June last year for up to five programs, including the lead programme, an affinity enhanced T-cell immunotherapy (GSK3377794) targeting NY-ESO-1, one of the best-characterised and most immunogenic cancer antigens frequently expressed by tumours. GSK can license the programme if it chooses to.
{iframe}http://www.pharmatimes.com/Article/16-02-02/GSK_Adaptimmune_expand_cancer_immunotherapy_alliance.aspx{/iframe}